Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BE Inc., GVK BIO ink deal
October 2019
SHARING OPTIONS:

HYDERABAD, India—A strategic collaboration between contract research and development organization GVK BIO and BE Pharmaceuticals Inc., a subsidiary of Biological E. Limited, is underway in the field of drug development. Per the agreement, GVK BIO will develop injectable products for BE Pharmaceuticals, with development work including pre-formulation studies, formulation development, analytical method development and technology transfer to a BE facility. The ultimate goal is to file all necessary regulatory submissions and marketing authorizations for the products in the U.S., Europe and rest of world markets.
“GVK BIO’s Formulations Development team has the technical expertise and track record to deliver on projects, and we look forward to working with the BE team to accelerate product development timelines and reduce cost to market,” said Manni Kantipudi, director and CEO of GVK BIO.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.